Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 12,587	$ 16,952
Available-for-sale investments	38,050	14,737
Other receivables	89	2,039
Prepaid expenses	1,408	1,803
Total current assets	52,134	35,531
Property and equipment, net	874	899
Right-of-use assets	1,886	2,083
Other assets	234	213
Total assets	55,128	38,726
Current liabilities:
Accounts payable	1,161	1,431
Accrued expenses	2,400	3,572
Current portion of operating lease liability	890	861
Total current liabilities	4,451	5,864
Long-term operating lease liability, net of current portion	1,145	1,378
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock, $0.001 par value per share; 5,000,000 undesignated authorized shares; Class X Convertible Preferred Stock issued and outstanding shares – 0 as of March 31, 2021 (unaudited) and December 31, 2020, respectively
Common stock, $0.001 par value per share; 21,425,000 authorized shares as of March 31, 2021 and December 31, 2020, respectively; issued and outstanding shares – 16,011,385 (unaudited) and 11,018,954 as of March 31, 2021 and December 31, 2020, respectively	16	11
Additional paid-in capital	395,422	370,210
Accumulated other comprehensive loss	(57)	(43)
Accumulated deficit	(345,679)	(338,528)
Total aTyr Pharma stockholders’ equity	49,702	31,650
Noncontrolling interest in Pangu BioPharma Limited	(170)	(166)
Total stockholders' equity	49,532	31,484
Total liabilities and stockholders’ equity	$ 55,128	$ 38,726